The Biotech sector is facing several challenges that threaten and limit its competitiveness in the EU, among them: regulatory barriers, R&D investment gap, global competition, supply chain vulnerabilities. EU needs to operate decisive actions to tackle those challenges and enable its biotech industry and the ones behind them, to grow and create value.
MK
Merck KGaA
Company · Germany · EU Transparency Register 49654992078-52
6
positions filed
in the 326 files tracked
6
legislative files
of 326 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #111 by legislative files engaged — a count of participation, not a measure of influence.
4.4
declared lobbying FTE
self-declared
€1.8M+
declared costs / yr (floor)
7
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
- Merck is a member of CEFIC (EU)
- EFPIA (EU)
- EBE - European Biopharmaceutical Enterprises (EU)
- EuropaBio →
- BVAC (DE with EU-office)
- VCI (DE) and its sub-state organisations such as LV Hessen
- and DIB (Deutsche Industrievereinigung Biotechnologie)
- Bundesverband der deutschen Industrie (BDI)
- Verband forschender Arzneimittelhersteller (DE)
- World Economic Forum (WEF)
- Bitkom (DE)
- European Round Table for Industry (ERT) →
- and 6 more
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- Merck
- Head office
- Darmstadt, Germany
- EU office
- Brüssel
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Merck in PolicySpeak: request access →
Work at Merck KGaA? so we know who speaks for it.
Their record over time
Merck KGaA filed 6 positions between 21 Mar 2024 and 3 Aug 2026, across 6 of the 326 legislative files tracked here, attaching a full position paper 3 times.
2024 · 2 filed2025 · 1 filed2026 · 3 filed
What they argued
Merck fully endorses the EU Safe Hearts Plan ambitions and welcomes CV Health Checks as a key EU initiative to advance population-level prevention and early disease detection. We stand ready to support its implementation from 2026 onwards, promoting harmonized, equitable monitoring of major cardiovascular risks to identify at-risk individuals and enable Member States to build consistent, evidence-based national…
Merck Life Science response to EU public consultation on Digital Product Passports rules for service providers public consultation: Merck Life Science would like to provide feedback on several key requirements that are essential for the successful implementation of Digital Product Passports (DPP). We supply scientists with the tools to carry out their work.
Merck KGaA supports a truly harmonised EU market with clear, predictable rules that protect human health and the environment while enabling access to effective biocidal products. In our view, the current functioning of the BPR does not meet these needs.
Merck welcomes the opportunity to comment on the proposals by the Commission to streamline regulatory processes and to improve cooperation between the agencies responsible for chemical management in the EU. Merck develops, manufactures, and markets high-quality medicines, innovative products for the biotech and pharmaceutical industries and for academic research as well as specialty chemicals for high-tech…
Regarding Annex II of the draft amending regulation (Ares (2026) 7318336) (which refers to Annex V of EU Regulation 649/2012), we encourage you to provide us with support in implementing the regulations by listing CAS numbers in full, rather than concluding them with the phrase and others.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- Cefic · 4 files in common
- MedTech Europe · 4 files in common
- IDEE ECONOMICHE www.idee-economiche.it · 3 files in common
- Japan Business Council in Europe · 3 files in common
- EFPIA · 3 files in common
Showing 5 of 48.
Is this your organization?
Everything on this page comes from Merck KGaA’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.